|
|
|
|
|
by maxst
3144 days ago
|
|
>Most of the major pharmaceutical companies continue to pursue the amyloid and tau pathways. Dementia Discovery Fund complements their work by supporting startups as they explore less mainstream approaches to treating dementia. That's very encouraging. Because what if it's something else? |
|
If it's something else, then chances are good it'll be far harder to fix, perhaps even requiring genetic engineering or medical nanotechnology. Finding out is still valuable, of course...